Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune & Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TEC/PSCTK4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TEC/PSCTK4 Full-Length & Kinase Domain Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View TEC/PSCTK4 Products |
| Gene Delivery | TEC/PSCTK4 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Selection markers available. |
View TEC/PSCTK4 Products |
| Benchmark Ab | Anti-TEC/PSCTK4 Recombinant Antibody Research-grade positive control for WB, IP, and Flow. |
View TEC/PSCTK4 Products |
| Validator | TEC/PSCTK4 siRNA Set For knockdown verification. |
View TEC/PSCTK4 Products |
| Related Target: BTK | Bruton's Tyrosine Kinase (BTK) Subfamily counter-screening essential for selectivity profiling. |
View BTK Products |
| Related Target: ITK | IL2-Inducible T-Cell Kinase (ITK) T-cell specific Tec family member; critical for immune selectivity assays. |
View ITK Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily selectivity (BTK/ITK/BMX off-target) | High-purity TEC, BTK, ITK, and BMX orthologs available for strict selectivity profiling; accurate IC50 ranking using sequence-verified proteins. |
| Cross-species cyno/mouse PK/PD evaluation | Human, Mouse, and Cynomolgus TEC ortholog proteins; Sequence Verified; HEK293 Expressed (Native Glycosylation). |
| Resistance mutation screening | TEC Kinase Domain mutant panel (gatekeeper, activation loop); Custom variants available; Sequence Verified. |
| Covalent Inhibitor Validation | Native active conformation kinase domains, confirmed via intact mass spec for precise binding kinetics. |
| Cellular target engagement & specificity | Premade Lentivirus for stable TEC-overexpressing cell lines; Matched TEC siRNA available for cellular specificity control. |
Live TEC/PSCTK4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TEC/PSCTK4 therapeutics is intensifying, with major players shifting focus from pan-Tec family inhibitors to highly selective TEC modulation. Early small molecule inhibitors successfully validated the pathway in B-cell malignancies, but off-target effects (e.g., BTK/TEC dual inhibition leading to hemorrhage) have driven the next wave of R&D toward highly selective non-covalent inhibitors and PROTAC degraders. Key trends include: (1) expanding from oncology to chronic autoimmune disorders, requiring exquisite kinase selectivity; (2) addressing acquired resistance mutations (e.g., gatekeeper mutations) through next-generation inhibitors; (3) rational combination strategies with BTK/SYK pathway modulators. As the focus expands into autoimmune indications, the requirement for minimized off-target risks has become the central pillar of modern TEC drug discovery.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Covalent) | AbbVie, Johnson & Johnson | B-cell Malignancies | Selectivity Assay (Need High-Purity TEC/BTK/ITK panel) |
| Small Molecule (Non-Covalent) | Eli Lilly, Merck | Autoimmune Diseases | Resistance Assay (Need Mutant Kinase Variants) |
| PROTAC / Degrader | Nurix Therapeutics | Refractory Lymphoma | Degradation Assay (Need Lentivirus for Stable Cell Lines) |
| Allosteric / Non-ATP Comp. | Emerging biotech & academic partners | Inflammation | Conformation-specific Assay (Need Full-Length TEC protein for SPR) |
TEC/PSCTK4 Molecular Characteristics
- Functional Domains: PH domain (UniProt P42680), SH3 domain, SH2 domain.
- Key Mutations: rs35374286 (dbSNP, UniProt VAR_041850); somatic mutation in a lung adenocarcinoma sample (UniProt VAR_041851).
- Resolved Target Identity: Although requested as TEC/PSCTK4, the primary entry (UniProt P42680) resolves to TEC (Tec protein tyrosine kinase). All reagents and assays are designed accordingly.